Terazosin Hydrochloride
Product Images NDC 53808-0307

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 53808-0307). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Terazosin HCl 1 mg Caps (Terazosin 1mg(cadista))

Label of Terazosin Hydrochloride 1 mg dosage form with a quantity of 30 units. The label includes lot number BP164, expiration date May 31, 2005, and notes it is packaged by DOH Central Pharmacy in Tallahassee, FL 32304. The label states 'RX Only' and has a barcode with UPC 359746383091.*

FDA Label Image

Terazosin HCl 2 mg Caps (Terazosin 2mg(cadista))

Label for Terazosin Hydrochloride 2 mg capsules in a quantity of 30, marked RX Only. The label includes lot information, expiration date, and indicates packaging by the State of Florida DOH Central Pharmacy in Tallahassee, FL. A UPC barcode is also visible.*

FDA Label Image

Terazosin HCl 5 mg Caps (Terazosin 5mg(cadista))

Label for Terazosin Hydrochloride 5 mg capsules, prescription only, packaged by State of Florida DOH Central Pharmacy in Tallahassee, FL. The label indicates a quantity of 30 capsules, a lot number, expiration date, and includes a barcode and UPC number.*

FDA Label Image

Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride, showing its molecular framework with labeled atoms and bonds, including the hydrochloride (HCl) salt form and molecular formula C19H25N5O4·HCl.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

Figure 1 from Study 1 consists of two line graphs comparing Terazosin with placebo over a 3-month period. The left graph shows mean change in total symptom score from baseline, with Terazosin showing a greater decrease than placebo. The right graph depicts mean increase in peak flow rate (mL/sec) from baseline, with Terazosin showing a greater increase compared to placebo. Sample sizes are indicated for each group.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

Line chart titled 'Mean Change in Total Symptom Score from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months (0 to 30), and the y-axis shows the mean change from baseline, which is 10.7. Data points show a decreasing symptom score over time with several points statistically significant (marked with asterisks) compared to baseline.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph titled 'Figure 3' showing the mean change in peak flow rate from baseline over a 30-month period in a long-term, open-label, non-placebo controlled study with 494 participants. The y-axis measures mean change from baseline in liters per second, ranging from 0 to 4.5, while the x-axis marks time in months from 0 to 30. Data points indicate statistically significant improvements at multiple time points compared to baseline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.